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Ginseng alone or combined with other herbs has been increasingly used for chronic obstructive
pulmonary disease (COPD). This review aims to evaluate the effectiveness and safety of oral
Ginseng formulae for stable COPD.
Four English databases and three Chinese databases were searched to identify randomized
controlled trials. Methodological quality was assessed by Cochrane risk of bias and Jadad’s
scale. Data were analyzed using Review Manager 5.0.
Twelve studiesoverall of lowquality, involving1560participantswere included. Results of three
studies showedamean difference (MD) of 0.30 (95%CI 0.02 to 0.58) for forced expiratory volume in
1 s (FEV1) improvement of Ginseng formulae versus placebo control. Findings of three studies re-
vealed an MD of 9.43 (95%CI 3.64 to 15.21) of FEV1 % predicted between Ginseng formulae and
placebo control. Quality of life (Qol) measured by St. George’s Respiratory Questionnaire wasedicine; CI, Confidence interval; COPD, Chronic obstructive pulmonary disease; FEV1, Forced expi-
global initiative for chronic obstructive lung disease; MD, Mean difference; Qol, Quality of life; RCTs,
ratio; SGRQ, St. George’s respiratory questionnaire.
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166 X. An et al.improved (MD 10.32, 95%CI 14.99 to 5.65) with Ginseng formulae plus pharmacotherapy
versus pharmacotherapy alone in one study. There were no severe adverse events reported.
Ginseng formulae for stable COPD patients show promising evidence of lung functions and Qol
improvement. However, the degree of benefit is uncertain due to potential risk of bias of the
included studies.
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Chronic obstructive pulmonary disease (COPD) is associated
with significant morbidity and mortality, and is predicted to
become the third leading cause of death worldwide by
2020.1,2 Over 10% of the global population (age 40 or older)
suffers fromstage II orhigherCOPDwith thefigurebeing14.3%
for the United States.3 In China, COPD affects 8.2% of indi-
viduals who are over 40 years old.4 COPD is characterized by
progressive, non-reversible airflow limitation.5 As there is no
cure, symptom management, quality of life (Qol) improve-
ment and reducing exacerbations become the primary treat-
ment objectives.6 It is generally understood that current
pharmacotherapy does not prevent progression of COPD nor
improve lung function.5 Moreover, they have been associated
with significant adverse events such as oropharyngeal candi-
diasis, bruising and risk of pneumonia.6 Complementary and
alternative medicines are increasingly being used by patients
with chronic disease.7 Herbal medicines are used by 14% of
adults with chronic pulmonary conditions and specifically,
Ginseng is used by 23% of herbal medicine consumers in the
US8 and 6% of the Victorian (Australia) herb users.9
In herbal medicine practice, stable COPD represents
a pattern of Qi deficiency involving either Lung or Spleen.
Qi is refined nutritive substance involved with functionalactivities.10 Ginseng, the root of a perennial plant, is
a single herb formula which is a potent tonic to restore and
replenish Qi of the Lung and Spleen to improve their
functions and it has been used for treating a wide range of
chronic respiratory conditions.11 There have been an
increasing number of Chinese herbal medicine (CHM) clin-
ical trials for the management of stable COPD including the
use of Ginseng formulae (i.e. a combination of several
herbal ingredients).12
A recent systematic review on CHM randomized controlled
trials (RCTs) administered orally or through intravenous
injection for both stable COPD and in acute exacerbation
concluded that CHM had potential benefits for COPD subjects
with Ginseng being one of the most commonly used herbs.13
Two out of 14 included studies involved the use of Ginseng
that demonstrated promising benefits of Ginseng for COPD.
However, Ginseng’s effectiveness and safety were not
specifically or thoroughly reviewed.
Orally administered CHM formulae is the traditional
administration method. The use of Ginseng extract for
intravenous and intramuscular injections is not commonly
practised in countries outside China. Therefore, to ensure
clinical relevance of findings from this review and allow
widespread application, this review is to evaluate the
effectiveness and safety of orally administered CHM
Figure 1 Flowchart of the study selection process.
Ginseng for chronic obstructive pulmonary disease 167formulae containing Ginseng or Ginseng extraction (here-
after, Ginseng formulae) for stable COPD.
Methods
Search strategy
Guided by the Cochrane Airways Group methodology,14 the
following electronic databases were searched: PubMed,
CINAHL, Cochrane Central Register of Controlled Trials
(CENTRAL), EMBASE, China National Knowledge Infrastruc-
ture (CNKI), Chinese Scientific Journals Full text Database
(CQVIP) and Wanfang, from their respective inceptions to
June 2009, without language restriction.
Search terms usedwere the combination of COPD, chronic
obstructive pulmonary disease, chronic obstructive lung
disease, chronic obstructive airway disease, chronic bron-
chitis, emphysema, pulmonary disease and complementary
therapies, Chinese herbal medicine, plant extracts, Chinese
herbs, Ginseng, randomized, controlled clinical trial and
their synonyms.
Study selection
RCTs on stable COPD patients of all stages, of any age,
gender or ethnic origin, with or without blinding were
considered. Orally administered interventions (i.e. decoc-
tion, capsule, tablet, pill or powder) of Ginseng CHM
formulae compared with placebo, no treatment, non-
Ginseng formulae or pharmacotherapy were examined.
Studies using Ginseng formulae combined with othertreatments such as acupuncture as a co-intervention were
excluded even if the same co-intervention was applied to
both arms. Included studies needed to report at least one
of the following four primary outcome measurements: 1)
Spirometric parameters; 2) Percentage of effectiveness of
symptom changes; 3) Quality of life; 4) Frequency of COPD
exacerbations. Adverse events reported in the included
studies are recorded as a secondary outcome measure.
Data extraction and quality assessment
Details of trial design, sample size, methodological quality,
participants, severity of COPD, syndrome differentiation,
intervention, outcome measures and adverse events of
each study were extracted.
Included studies were independently reviewed (XA and
AY) for methodological quality, using the Cochrane risk of
bias assessment15 consisting of six domains of potential bias
which were answered by denoting ‘yes’ (low risk of bias), or
‘no’ (high risk of bias) or ‘unclear’ (uncertain risk).15
‘Randomization’, ‘double blinding’ and ‘withdrawals and
dropouts’ were assessed using the Jadad’s scale (from
0 Z worst to 5 Z best).16 Any disagreement was resolved
by discussion with one of two other reviewers (AZ and CX).
Data analysis
Data were analyzed using RevMan 5.0 software, developed
by The Cochrane Collaboration. Dichotomous data were
presented as risk ratio (RR) and continuous outcomes as
mean difference (MD) with 95% confidence intervals (CI).
Heterogeneity was calculated by c2 and I2 statistics. Two
analysis models (random effects and fixed effects) were
applied. Thus, if I2 statistic was less than 50%, the fixed
effect model was applied whereas more than 50% the
random effect model was used.
Results
Description of studies
The initial searches identified 938 entries with 12 studies
meeting the selection criteria (Fig. 1), 11 were conducted
in China17e27 and one in Israel.28 The characteristics of the
included studies are summarized in Table 1. There were no
disagreements in data extraction between the two
reviewers. The 12 studies involved a total of 1560 stable
COPD patients, ranging from 36 to 600 with four studies
having more than 100 subjects.18,22,25,27 Eight subjects
dropped out and they were excluded in the original
report,28 and 1552 subjects (1050 males and 502 females,
mean age Z 63.73) were included in the data analysis.
As shown inTable 1, the severity of COPDof participants in
five studies17,19,22,23,25 were classified asmild,moderate and
severe. Three studies,18,20,21 based on the classifications
developed by the Chinese Medical Association of Respiratory
Diseases,29 stratified the severity of participants’ COPD as
stages I to III. One study28 adapted the American Thoracic
Society’s Standardization of Spirometry30 and moderate
severity of COPD was defined as FEV1 50e65% of predicted.
Table 1 Characteristics of included studies.
First author,
date (Ref)
Location
of Hospital
Source of
patients
Number of
Participants (R/A)
Number of
Male/Female
Age Mean 
SD (years)
Severity of COPD Syndrome
Differentiation
of CM
COPD History
Mean  SD
(years)
Chen, 200718 Chendu, China Outpatients T: 59/59 T: 45/14 T: 59.03  6.70 T: I: 13, IIA: 20, IIB: 18, III: 8 Lung & Kidney
deficiency
NS
C: 58/58 C: 42/16 C: 58.59  6.29 C: I: 16, IIA: 19, IIB: 17, III: 6
Chen, 200417 Nanping, China Inpatients T: 30/30 35/25 65.00  NA Mild 15, Moderate 26, Severe 19 NS 60.21  NS
C: 30/30
Gross, 200228 Tel Aviv, Israel NS T&C: 100/91 T: 30/21 T: 59.0  12.6 FEV1: 50e65% of predicted NS NS
T: 51; C: 41 C: 25/16 C: 62.0  10.5
Guo, 200819 Tangshan, China Outpatients T: 50/50 T: 36/14 T: 56.00  NA T: mild 8, moderate 33, severe 9 NS T: 16.00  NS
C: 50/50 C: 34/16 C: 55.00  NA C: mild 7, moderate 35, severe 8 C: 14.00  NS
Hong, 200520 Zhangzhou, China Inpatients &
outpatients
T: 18/18 T: 16/2 T: 67.56  5.19 T: II: 3, III: 15; C: II: 3, III: 15 Lung & Spleen &
Kidney deficiency
T: 15.22  5.12
C: 18/18 C: 15/3 C: 66.00  6.40 C: 14.17  6.15
Huang, 200521 Guangzhou, China Outpatients T: 32/32 T: 21/11 T: 69.50  11.80 T: II: 17, III: 15; C: II: 18, III: 13 NS T: 8.50  3.20
C: 31/31 C: 23/8 C: 68.80  10.60 C: 8.30  3.50
Huang, 200222 Xuzhou, China Inpatients &
outpatients
T: 300/300 T: 185/115 T: 52.50  4.40 Mild to moderate Lung & Kidney
deficiency
T: 7.20  4.40
C: 300/300 C: 202/98 C: 57.20  10.40 C: 8.50  3.60
Li, 200623 Zhengzhou, China NS T: 31/31 T: 22/9 T: 72.00  5.00 T: mild 5,moderate 21, severe 6 Lung & Kidney
deficiency
T: 18.40  1.10
C: 31/31 C: 23/8 C: 71.00  7.00 C: mild 4,moderate 21, severe 5 C: 19.50  6.60
Lin, 200324 Guangzhou, China Inpatients &
outpatients
T: 30/30 T: 20/10 T: 62.00  NS NS Spleen deficiency T: 16.00  NS
C: 30/30 C: 22/8 C: 60.50  NS C: 15.40  NS
Wu, 200625 Xinxiang, China Inpatients &
outpatients
T: 100/100 T: 68/32 T: 71.87  4.37 T: mild 21, moderate 48,
severe 31 C:
Lung & Kidney
deficiency
T: 18.70  3.72
C: 100/100 C: 72/28 C: 69.33  5.71 mild 23, moderate 51, severe 26 C: 17.81  4.57
Xiong, 200826 Shenzhen, China Inpatients &
outpatients
T: 30/30 T: 20/10 T&C: 72.00  NS Average of FEV1: 52.3% Lung & Kidney
deficiency
NS
C: 30/30 C: 21/9
Xu, 199627 Luzhou, China Inpatients &
outpatients
T: 72/72 T: 52/20 T: 63.50  NS; NS Qi deficiency T: 9.50  NS
C: 30/30 C: 21/9 C: 60.80  NS C: 9.00  NS
T: treatment; C: control; NS: not specified; COPD: chronic obstructive pulmonary disease; SD: standard deviation; CM: Chinese medicine.
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Table 2 Characteristics of interventions and outcome measures of included studies.
First author, date Intervention
(ingredients of
Ginseng formulae)
Controlled Interventions Jadad’s
scale
Duration/
Follow-up
Adverse
event
Outcome measures
Spirometric
parameter
PESI Validated
QoL
FCOPDE
Chen, 200718 Feikongning capsule (Panax Ginseng,
Cordyceps, Radix Salviae Miltiorrhizae,
Semen Armeniacae Amarum),
3 capsules, 3 times daily
Jinshuibao capsules
(Fermented
Cordyceps powder),
3 capsules, 3 times daily
2 3 mths/6 mths No Yes Yes No Yes
Chen, 200417 Yifei pill (Panax Ginseng, Gecko,
Fructus Psoraleae) 2 pills,
3 times daily
Pharmacotherapy (NS) 1 3 mths/NS NS Yes NS No NS
Gross, 200228 Panax Ginseng extract 100 mg,
twice daily
Placebo control 5 6 mths/NS No Yes NS No NS
Guo, 200819 Jianfei capsule (Panax Ginseng, Gecko,
Fagopyrum cymosum Meisn,
Bulbus Fritillariae Cirrhosae,
Lumbricus, Semen Armeniacae
Amarum) 2e3 pills,
3 times daily þ Pharmacotherapy
(Long acting b2 agonists & Theophyline)
Pharmacotherapy
(Long acting b2 agonists &
Theophyline)
1 1 month/NS NS NS Yes No NS
Hong, 200520 Yufeining pill (Panax Ginseng,
Radix Astragali,
Rhizoma Atracylodis Macrocephalae,
Radix Saposhnikoviae,
Placenta Hominis, Semen
Armeniacae Amarum,
Semen Cuscutae, Fructus Corni,
Fructus Schisandrae,
Semen Juglandis, Fructus Trichosanthis,
Semen Persicae) 6 g, twice daily
No treatment 2 6 mths/6 mths No Yes NS No Yes
Huang, 200521 Jianpiyifei granule (Panax Ginseng,
Rhizoma Atracylodis Macrocephalae,
Poria, Radix Ophiopogonis, Cortex Mori,
Radix Astragali) 10 g, 3 times daily
Pharmacotherapy (NS) 1 3 mths/6 mths Mild Yes NS Yes Yes
Huang, 200222 Bufeiguben granule (Panax Ginseng,
Gecko, Herba Epimedii, Semen Juglandis,
Fructus Psoraleae, Fructus Schisandrae),
10 g, 3 times daily
Placebo (Hawthorn) 1 1 month/NS NS Yes NS No NS
(continued on next page)
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Table 2 (continued )
First author, date Intervention
(ingredients of
Ginseng formulae)
Controlled Interventions Jadad’s
scale
Duration/
Follow-up
Adverse
event
Outcome measures
Spirometric
parameter
PESI Validated
QoL
FCOPDE
Li, 200623 Bufeiyishen granule
(Panax Ginseng, Radix Astragali,
Radix Saposhnikoviae, Fructus
Psoraleae, Fructus Schisandrae,
Szechwan Lovage Rhizome, Semen
Armeniacae Amarum, etc.)
10 g, 3 times daily
Placebo control
(Hawthorn fruit and Malt)
2 2 mths/NS NS Yes NS No NS
Lin, 200324 Jianpiyifei granule (Radix Ginseng,
Rhizoma Atracylodis
Macrocephalae, Poria,
Radix Ophiopogonis,
Cortex Mori, Radix Astragali),
10 g, 3 times daily
Placebo control
(Stroma granule)
1 2 mths/NS NS Yes Yes No NS
Wu, 200625 Jiaweishenge granule (Panax Ginseng,
Gecko, Semen Armeniacae Amarum, Bulbus
Fritillariae Cirrhosae, Poria, Cortex Mori,
Radix Astragali, Rhizoma Atracylodis
Macrocephalae, Cordyceps,
Szechwan Lovage Rhizome,
Lumbricus) 60.5 g/packet,
1 packet, 3 times daily
Placebo control
(Hawthorn, Fructus Hordei
Germinatus, medicated leaven)
1 2 mths/NS No Yes NS No NS
Xiong, 200826 Shenge granule (Panax Ginseng,
Gecko), 5 g, twice daily
Pharmacotherapy
(Inhaled Salmeterol &
fluticasone, 50/250 ug,
one puff, twice daily)
1 6 mths/NS NS Yes Yes No NS
Xu, 199627 Yiqimianyi granule
(Panax Ginseng, Rhizoma
Atracylodis Macrocephalae, Poria)
20 g, 3 times daily
Zhenqi Fuzheng granule
(Fructus Ligustri Lucidi,
Radix Astragali) 15 g, twice daily
1 30 days/NS NS NS Yes No NS
NS: Not specified; PESI: Percentage of effectiveness of symptoms improvement; QoL: Quality of life; FCOPDE: Frequency of COPD exacerbation.
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Figure 2 Summary of assessment of risks of bias
+ Yes (low risk of bias) ? Unclear (uncertain risk) − No (high risk of bias)
Ginseng for chronic obstructive pulmonary disease 171Three studies24,26,27 did not specify the stages of COPD of the
participants, and none of the papers referenced quality
standards of spirometry performance.31
Guided by Chinese medicine syndrome differentiation
guidelines such as the Chinese Medicine Clinical Research
Guidelines for New Drugs,32 eight studies reported stable
COPD patients as Lung deficiency with Kidney and/or
Spleen deficiency18,20,22e26 or Qi deficiency.27
Six of the 12 studies compared oral Ginseng formulae with
placebo or no treatment.20,22e25,28 Two studies comparedGinseng formulae with other oral CHM formulae without
Ginseng.18,27 Four studies compared the Ginseng formulae
plus pharmacotherapy or Ginseng formulae alone with phar-
macotherapy (inhaled b2 agonist and anti-cholinergic or oral
theophylline alone)17,19,21,26 (Table 2). Duration of treatment
ranged from onemonth in three studies,19,22,27 twomonths in
three studies,23e25 three months in three studies,17,18,21 and
six months in three studies.20,26,28 Three studies mentioned
a 6-month follow-up period.18,20,21 None of the included
studies mentioned a run-in period.
Methodological quality
Assessment of risk of bias
Information of sequence generation was adequate for three
studies at low risk of bias (yes)18,20,28 and inadequate for
nine studies with unclear risk of bias (unclear).17,19,21e27
The methods of allocation concealment were judged with
‘unclear’ in all studies. Blinding was reported in two studies
with one described as double blind28 and another as single
blind.21 However blinding of participants, personnel and
outcome assessors in all studies was ‘unclear’. Low risk of
bias from incomplete outcome data was noted in 11 stud-
ies,17e21,23e28 one was ‘unclear’22. Intention-to-treat
analysis was not conducted in any of these studies. Selec-
tive outcome reporting was at low risk of bias in six stud-
ies18,21e24,27 and at high risk of bias in six
studies.17,19,20,25,26,28 Assessments of other sources of bias
included early stopping and baseline imbalance. All 12
studies indicated no significant difference of baseline data
between two groups; none of studies reported sample size
calculation method, therefore information on early stop-
ping was insufficient. Overall, other sources of bias were
‘unclear’. Detailed information is provided in Fig. 2.
Assessment of Jadad’s scale
Only one study was rated with a score of 5 (highest
quality)28; three studies with a score of 218,20,23 and eight
studies with a score of 117,19,21,22,24e27 (Table 2).
Outcome measures
Spirometric parameters
Pre and post-treatment mean FEV1
18,20e23,25,26 (Fig. 3)
and FEV1 % predicted
17,18,20,23e26 (Fig. 4) were reported
in seven studies respectively. Another study did not
report post-treatment FEV1
28 and it was not included in
this analysis. Marginal but significant differences in
absolute FEV1 (MD 0.30, 95%CI 0.02 to 0.58)
22,23,25 and
FEV1 % predicted (MD 9.43, 95%CI 3.64 to 15.21)
23e25
were found between Ginseng formulae and placebo.
Similar changes were shown in studies comparing Ginseng
Formulae with non-ginseng formulae, absolute FEV1 (MD
0.25, 95%CI 0.06 to 0.44), and FEV1% predicted (MD 4.76,
95%CI 0.36 to 9.16)18. Such changes were not observed
using Ginseng formulae alone versus no treatment (FEV1
[MD 0.10, 95%CI 0.11 to 0.31] and FEV1 % predicted [MD
2.32, 95%CI 6.84 to 11.48])20 or versus pharmaco-
therapy alone (FEV1 [MD 0.25, 95%CI 1.84 to 2.34] and
FEV1 % predicted [MD 2.03, 95%CI 2.63 to 6.69])26 (Figs.
3 and 4).
Figure 3 Ginseng formulae versus placebo, no treatment, non-Ginseng formulae, or pharmacotherapy for pre-post changes of
FEV1 (L) of patients with stable COPD, Review: Ginseng formulae for stable COPD, Comparison: 1.3.1 Ginseng formulae Vs placebo;
1.3.2 Ginseng formulae Vs no treatment; 1.3.3 Ginseng formulae Vs non-Ginseng formulae; 1.3.4 Ginseng formulae alone Vs
pharmacotherapy; 1.3.5 Ginseng formulae plus pharmacotherapy Vs pharmacotherapy.
172 X. An et al.Symptom improvement
Ginseng formulae group showed higher percentage of
symptom improvement when compared with placebo (RR
1.53, 95%CI 1.09 to 2.16)24, or non-ginseng formula group
(RR 1.11, 95%CI 1.00 to 1.24)18,27 as well as plus pharma-
cotherapy versus pharmacotherapy (RR 1.14, 95%CI 1.00 to
1.31)19. However such change was not observed using
Ginseng formulae alone versus pharmacotherapy alone (RR
1.17, 95%CI 0.93 to 1.48)26 (Fig. 5).
Quality of life
In the study in which Qol was measured by using a validated
instrument (St. George’s Respiratory Questionnaire SGRQ),
there was an improvement in the SGRQ when comparing
Ginseng formulae plus pharmacotherapy to pharmacotherapy
alone (MD 10.32, 95%CI 14.99 to 5.65)21. Furthermore,
positive Qol improvementwas also reported by another study20
using a self-modified questionnaire developed by Cai et al.
COPD exacerbations
Two studies18,21 reported COPD exacerbation during the
follow-up period. Significant reduction in the number of
patients developing COPD exacerbations was reported in the
study using a Ginseng formula compared to a non-Ginsengformula (RR 0.40, 95%CI 0.18 to 0.90)18, but no additional
benefit of a Ginseng formula to pharmacotherapy was shown
(RR 0.68, 95%CI 0.42 to 1.09)21. In addition, one study
comparing Ginseng formula with no treatment and reported
that the number of COPD exacerbations per annum was
significantly less in the treatment group (MD 1.52 95%CI
2.32 to 0.72).20
Adverse events
One study involving 63 subjects stated that dry mouth, mild
stomachbloatingand reducedappetitewereobserved in three
subjects (twofromtreatmentgroupandone incontrol groups).
These symptoms disappeared within one week without
medical interventions.21 Four studies reported that therewere
no adverseevents in those trials.18,20,25,28 The remaining seven
studies did not report adverse events.17,19,22e24,26,27
Discussion
This review shows that the Ginseng formulae were more
effective in improving FEV1when comparedwith placebo
22e25
or non-Ginseng formulae18 for stable but various stages of
COPD subjects. Ginseng formulae were also associated with
higher percentages of symptom improvement versus placebo
Figure 4 Ginseng formulae versus placebo or no treatment control, non-Ginseng formulae and pharmacotherapy for pre-post
changes of FEV1% predicted of patients with stable COPD, Review: Ginseng formulae for stable COPD, Comparison: 1.1.1 Ginseng
formulae Vs placebo; 1.1.2 Ginseng formulae Vs no treatment; 1.1.3 Ginseng formulae Vs non-Ginseng formulae; 1.1.4 Ginseng
formulae alone Vs pharmacotherapy; 1.1.5 Ginseng formulae plus pharmacotherapy Vs pharmacotherapy.
Ginseng for chronic obstructive pulmonary disease 173or pharmacotherapy.18,19,24,27 A Ginseng formula was benefi-
cial for Qol based on SGRQ21 and two Ginseng formulae
reduced the frequencyofexacerbations.18,21 Overall,Ginseng
formulae were well tolerated by subjects.
Unlike Guo’s review,13 this study focuses on evaluating
the effectiveness of oral use Ginseng formulae for stable
COPD based on assessment of FEV1, symptom improvement,
Qol and frequencies of exacerbations.
The majority of the 12 included studies suffered from
methodological weaknesses based on assessment of the
Cochrane risk of bias and the Jadad’s scale. The inadequacy
of blinding and placebo control,33 allocation concealment
and sequence generation,34 were the major sources of
potential bias. As well as treatment durations ranging from
one month19,22,27 to six months20,26,28 and using Ginseng
formulae as an add-on treatment on routine pharmaco-
therapy for COPD.17,19,21,26 Therefore, findings from this
review need to be interpreted with caution.
Despite the methodological weakness and potential risk of
bias, the findings of the present review are promising.
Particularly the improvement of the lung functions based on
pre-post FEV1 and FEV1 % predicted between Ginseng
formulae and placebo or no treatment or non-Ginseng
formulae groups. These findings are consistent with recent
RCTs on effect of a phosphodiesterase-4 (PDE4) inhibitor(roflumilast)35 on lung function in patients with moderate to
severe COPD who were on salmeterol and tiotropium treat-
ment. The two trials, involving 1676 COPD subjects concluded
that, compared with placebo, 24 weeks of roflumilast treat-
ment significantly and consistently improved mean pre and
post-bronchodilator FEV1 (p < 0.0001).
A large study involving almost 6000 subjects conducted in
37 countries demonstrated that prolonged intervention (4
years) of a long acting bronchodilator, tiotropium, on
moderate COPD patients (GOLD Stage II) was effective in
reducing the rate of decline of post-bronchodilator FEV1.
However, such changes were not shown in prebronchodilator
FEV1 between the treatment groups.
36 Tiotropium also
improved the general health status,Qol basedonSGRQaswell
as reducing frequencies of exacerbations and subsequent
hospitalisations.37 It was therefore concluded earlier and
long-term intervention is critical to the treatment of COPD.
When Ginseng formulae were compared with placebo or
non-Ginseng formulae, the observed benefits were clearly
demonstrated.17,18,22e26 Such findings showed the poten-
tially important role that Ginseng might have played in
these studies, particularly in the study that only a stan-
dardized Ginseng extract was used.28
Ginseng as the key herb possesses a broad range of
pharmacological activities which may offer plausible
Figure 5 Ginseng formulae versus placebo or no treatment control, non-Ginseng formulae and pharmacotherapy for pre-post
changes of improvement of effective rate of patients with stable COPD, Review: Ginseng formulae for stable COPD, Comparison:
1.2.1 Ginseng formulae Vs placebo; 1.2.2 Ginseng formulae Vs non-Ginseng formulae; 1.2.3 Ginseng formulae alone Vs pharma-
cotherapy; 1.2.4 Ginseng formulae plus pharmacotherapy Vs pharmacotherapy.
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review. For example, Ginseng raw extract or purified gin-
senosides have been shown to enhance markedly the action
of the diterpene forskolin in elevating intracellular Cyclic
adenosine monophosphate (cAMP) levels in rat cultured
glioma cell.38 Two ginsenosides, panaxadiol (PD) and pan-
axatriol (PT) have been shown to have potent inhibitory
effects on the expression of matrix metalloproteinase-9
(MMP-9).39 Compound K of ginseng showed similar effects in
an experiment with human astroglioma cells.40 In smokers,
ginseng taken daily for 4 weeks has been found to linearly
increase plasma concentrations of certain antioxidants.
These findings are significant since oxidative damage
caused by free radicals associated with smoking is thought
to contribute to the development of COPD.41 Proto-
panaxadiol ginsenosides (PPDGs) such as Rb1 and Rb2 have
been demonstrated to have significant potency as inhibitors
of lipopolysaccharide-induced production of tumor necrosis
factor-alpha (TNF-a) in murine (RAW264.7) cells and human
(U937) macrophages.42 This effect was significantly
enhanced by various TNF-a antagonists.42
It is also important to note that due to the heterogeneity
of the studies included in this review, the observed benefitscould be a combined outcome of inclusion of unspecified
proportion of various stages of COPD, the use of a range of
herbal formulations, the uncertain quality of spirometric
measurements; and the potential of real benefit of Ginseng
in treating COPD.
Generally speaking adverse event reporting in the
included studieswas inadequate. However, the safety profile
of Ginseng has been demonstrated in a systematic review,
concluding that Panax ginseng mono-preparations are rarely
associated with adverse events or drug interactions.43
Conclusion
Despite the quality concerns of the included studies, the
observed benefits of Ginseng formulae are encouraging.
Further trials are warranted to determine the true benefits
of Ginseng which also address the methodological problems
identified in this review.
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